Sipuleucel‐T is the first FDA‐approved immunotherapy for prostate cancer patients, the recombinant fusion prostatic acid phosphatase (PAP) can activate antigen‐presenting cells (APCs) and shift the immunosuppressive milieu of tumors [10]. This evidence concerns the gene ACP3 and prostate carcinoma.